(redirected from Vantas)


a synthetic preparation of gonadotropin-releasing hormone, used as the acetate ester in treatment of precocious puberty.


(hiss-tre-lin) ,

Supprelin LA

(trade name),


(trade name)


Therapeutic: hormones
Pharmacologic: gonadotropin releasing hormones
Pregnancy Category: X


Palliative treatment of advanced prostate cancer (Vantas).Central precocious puberty (Supprelin LA).


Continuous administration decreases production of gonadotropins.

Therapeutic effects

Suppression of testosterone production.
Prevention of disease progression.


Absorption: Highly absorbed (92%) from implant. Peak absorption occurs at 12 hours, and continues over 1–year period.
Distribution: Unknown.
Protein Binding: 29%.
Metabolism and Excretion: Unknown.
Half-life: 3.92 hours.

Time/action profile (↓ in LH, FSH, and sex-steroid levels)

Subcutunknown12 hr52 wk


Contraindicated in: Hypersensitivity to any component of the product, GnRH, or GnRH agonist analogs; Women.
Use Cautiously in: Patients with metastatic vertebral lesions or urinary tract obstruction (initial transient ↑ in testosterone may worsen symptoms); Pediatric: Children <2 yr (safety not established) (Supprelin LA).

Adverse Reactions/Side Effects

Central nervous system

  • stroke (life-threatening)
  • headache (most frequent)
  • anxiety
  • depression
  • dizziness
  • insomnia
  • irritability
  • lethargy
  • malaise
  • seizures

Ear, Eye, Nose, Throat

  • visual disturbances


  • dyspnea


  • Myocardial infarction (life-threatening)
  • vasodilation (most frequent)
  • edema
  • palpitations
  • tachycardia


  • hepatotoxicity (life-threatening)
  • abdominal discomfort
  • constipation
  • nausea
  • vomiting


  • dysuria
  • hematuria
  • polyuria
  • urinary retention


  • acne
  • ↑ sweating
  • pruritis
  • rash


  • breast discharge
  • breast pain
  • genital pruritis
  • ↑ breast size


  • anemia


  • itching, erythema, and swelling at implantation site (most frequent)


  • hypercalcemia
  • hyperglycemia
  • hyperlipidemia


  • arthralgia
  • bone pain
  • joint stiffness
  • muscle cramps
  • muscle stiffness
  • myalgia


  • tremor


  • allergic reactions including angioedema (life-threatening)
  • hot flashes (most frequent)
  • ↑ appetite
  • ↑ pain


Drug-Drug interaction



Prostate Cancer

Subcutaneous (Adults) 50 mg implant inserted every 12 mo.

Central Precocious Puberty

Subcutaneous (Children ≥2 yr) 50 mg implant inserted every 12 mo.


Injection: 50 mg/implant

Nursing implications

Nursing assessment

  • Obtain a complete physical and endocrinologic examination, including height, weight, before starting, after 3 mo and every 6–12 mo during therapy.
  • Assess for signs of disease progression periodically throughout therapy.
  • Monitor patient for signs of hypersensitivity (angioedema, urticaria, hypotension, tachycardia, loss of consciousness, bronchospasm, dyspnea, flushing, pruritus). Discontinue therapy if any of these symptoms occur.
  • Lab Test Considerations: Monitor LD, FSH, estradiol, or testosterone at 1 mo after implantation and every 6 mo thereafter.
    • May cause ↑ AST and LDH; usually reversible with removal of implant.

Potential Nursing Diagnoses

Sexual dysfunction (Indications)
Deficient knowledge, related to medication regimen (Patient/Family Teaching)


  • Subcutaneous: Histrelin is given as a single yearly subcutaneous implant. The implant must be removed after 12 mo of therapy. Subsequent implantation may be used to continue therapy.

Patient/Family Teaching

  • Instruct patient to not to get arm wet for 24 hrs and to avoid strenuous lifting for 7 days after insertion.
  • Inform patient and family that if implants are not given yearly, disease may progress.
  • Advise patient and family that during initial agonistic phase (1–3 wk) the patient may have transient symptom worsening or onset of new symptoms, including bone pain, neuropathy, hematuria, or urinary tract obstruction.
  • Inform patient and family that redness or swelling may occur at the implantation site, especially after initial implantation or implant removal. Notify health care professional if this reaction is severe or does not go away.
  • Instruct patient and family to contact health care professional at the first sign of skin rash, urticaria, rapid heartbeat, difficulty swallowing or breathing, or any swelling that may suggest angioedema.

Evaluation/Desired Outcomes

  • Palliation of signs and symptoms associated with prostate cancer.
  • Delay of early onset of puberty.


/his·trel·in/ (his-trel´in) a synthetic preparation of gonadotropin-releasing hormone, used as the acetate ester in the treatment of precocious puberty.
References in periodicals archive ?
We'll eat our penny fades, soda cakes Drink Vantas too Then in the interval head straight for the loo When the film has ended We spill os ut into the light We'll go home to have our tea The the lads will play cowies all night Slapping their bums shouting "Gee Up, Trigger" Then chase the girls up and down the jigger We all go off home, tired yet glad Thankful for the smashing day that we've just had Lil Bordesa, L5
Medications in the GnRH class are marketed under the brand names Eligard, Lupron, Synarel, Trelstar, Vantas, Viadur, and Zoladex.
The FDA has not made any conclusions about whether diabetes or these cardiovascular diseases are caused by treatment with these drugs, which are available in generic formulations and as brand-name products (Lupron, Eligard, Synarel, Trelstar, Vantas, Viadur, and Zoladex).
The company markets VANTAS for advanced prostate cancer and has multiple products in clinical development including SUPPRELIN-LA for central precocious puberty.
Tendremos vantas y axportacionas mucho mayoras qua las da Fiat, y ampleamos a mas personas.
Valera markets VANTAS for advanced prostate cancer and has multiple products in clinical development including SUPPRELIN-LA for central precocious puberty.
We'll eat our penny fades, soda cakes, Drink Vantas too, Then in the interval head straight for the loo.
Among Indevus products is Vantas, a soft and flexible implant for the palliative treatment of advanced prostate cancer.
with exclusive marketing and distribution rights to VANTAS and SUPPRELIN-LA for the European Union, Switzerland, and Norway.
The long-acting drug delivery mechanisms of VANTAS and SUPPRELIN-LA are based on Valera's proprietary Hydron implant technology.
In addition to our currently marketed VANTAS, this includes VALSTAR(R), the only approved drug therapy for certain urinary bladder cancer patients, which we recently acquired and expect to launch around year-end 2006.
For the first quarter ended March 31, 2006, unit sales of VANTAS rose to 3,412 units, a gain of 17% from 2,925 units sold in the first quarter of 2005, and a gain of 19% from 2,868 units sold in the fourth quarter of 2005.